Atrium Therapeutics Q3 2026 net loss widens to $4.27 million

By Public Technologies21:27 (UTC), 12 November 2026 Updated

Atrium Therapeutics’ third-quarter 2026 net loss widened to $4.27 million from a year earlier.
Collaboration revenue rose 24% year over year to $15.32 million, primarily related to a Bristol Myers Squibb milestone.
Total operating expenses climbed 75% year over year to $21.95 million.
The first patient was dosed in Corventis, the ATR 1072 Phase 1/2 trial; initial proof-of-concept data are expected in second-half 2027.
Cash, cash equivalents and short-term investments totaled $232.1 million at September 30; anticipated cash runway extends through 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atrium Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA96095) on November 12, 2026, and is solely responsible for the information contained therein.